IL316465A - BCL-XL tetrahydroisoquinoline heterobifunctional compounds - Google Patents

BCL-XL tetrahydroisoquinoline heterobifunctional compounds

Info

Publication number
IL316465A
IL316465A IL316465A IL31646524A IL316465A IL 316465 A IL316465 A IL 316465A IL 316465 A IL316465 A IL 316465A IL 31646524 A IL31646524 A IL 31646524A IL 316465 A IL316465 A IL 316465A
Authority
IL
Israel
Prior art keywords
degraders
heterobifunctional
tetrahydroisoquinoline
bcl
tetrahydroisoquinoline heterobifunctional
Prior art date
Application number
IL316465A
Other languages
English (en)
Hebrew (he)
Original Assignee
Treeline Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Treeline Biosciences Inc filed Critical Treeline Biosciences Inc
Publication of IL316465A publication Critical patent/IL316465A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL316465A 2022-05-06 2023-05-04 BCL-XL tetrahydroisoquinoline heterobifunctional compounds IL316465A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263339253P 2022-05-06 2022-05-06
US202263398783P 2022-08-17 2022-08-17
US202263429862P 2022-12-02 2022-12-02
US202363449756P 2023-03-03 2023-03-03
US202363454545P 2023-03-24 2023-03-24
US202363457997P 2023-04-07 2023-04-07
PCT/US2023/021010 WO2023215482A1 (en) 2022-05-06 2023-05-04 Tetrahydroisoquinoline heterobifunctional bcl-xl degraders

Publications (1)

Publication Number Publication Date
IL316465A true IL316465A (en) 2024-12-01

Family

ID=86688472

Family Applications (1)

Application Number Title Priority Date Filing Date
IL316465A IL316465A (en) 2022-05-06 2023-05-04 BCL-XL tetrahydroisoquinoline heterobifunctional compounds

Country Status (13)

Country Link
US (1) US20240238423A9 (enExample)
EP (1) EP4519259A1 (enExample)
JP (1) JP2025517642A (enExample)
KR (1) KR20250008772A (enExample)
CN (1) CN119343345A (enExample)
AU (1) AU2023264018A1 (enExample)
CA (1) CA3251489A1 (enExample)
CL (1) CL2024003362A1 (enExample)
IL (1) IL316465A (enExample)
MX (1) MX2024013537A (enExample)
PE (1) PE20250007A1 (enExample)
TW (1) TW202400589A (enExample)
WO (1) WO2023215482A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023246924A1 (zh) * 2022-06-24 2023-12-28 南京瑞初医药有限公司 苯并噻唑化合物及其应用
KR20260111020A (ko) * 2023-11-07 2026-07-14 트리라인 바이오사이언시스, 인크. 테트라히드로이소퀴놀린 이종이작용성 bcl-xl 분해제
AU2024378690A1 (en) * 2023-11-07 2026-05-07 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-x l degraders
IL327973A (en) * 2023-11-07 2026-06-01 Treeline Biosciences Inc Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
AU2024409323A1 (en) * 2023-12-18 2026-07-09 Nanjing Reju Therapeutics Co., Ltd. Nitrogen heterocyclic compound and use thereof
WO2026102147A1 (en) * 2024-11-07 2026-05-15 Treeline Biosciences, Inc. Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
WO2026158623A1 (zh) * 2025-01-26 2026-07-30 南京瑞初医药有限公司 蛋白降解剂及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2493466T3 (es) 2005-05-12 2014-09-11 Abbvie Bahamas Ltd. Promotores de la apoptosis
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI571466B (zh) * 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
CN103987711B (zh) 2011-10-14 2016-08-24 艾伯维公司 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物
CN109152933B (zh) 2016-04-21 2022-12-02 生物风险投资有限责任公司 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途
ES3041854T3 (en) 2018-01-22 2025-11-17 Bioventures Llc Bcl-2 proteins degraders for cancer treatment
WO2020163823A2 (en) 2019-02-08 2020-08-13 University Of Florida Research Foundation, Incorporated Therapeutic agents and methods of treatment
AU2020310147A1 (en) 2019-07-10 2022-01-06 Recurium Ip Holdings, Llc Bcl-2 protein inhibitors
CN112707900B (zh) 2019-10-24 2022-06-10 上海科技大学 蛋白降解剂及其在疾病治疗中的应用
CA3163593A1 (en) 2020-01-15 2021-07-22 Guangrong Zheng Therapeutic agents and methods of treatment
CA3173843A1 (en) 2020-04-28 2021-11-04 Recurium Ip Holdings, Llc Bcl-2 protein inhibitors
JP2024505562A (ja) 2021-02-02 2024-02-06 レス ラボラトイレス セルビエル 選択的bcl-xl protac化合物及び使用の方法
WO2023044046A1 (en) 2021-09-17 2023-03-23 Kymera Therapeutics, Inc. Bcl-xl degraders and uses thereof
WO2023083194A1 (zh) * 2021-11-09 2023-05-19 杭州格博生物医药有限公司 Wee1蛋白激酶降解剂及其用途

Also Published As

Publication number Publication date
JP2025517642A (ja) 2025-06-10
WO2023215482A1 (en) 2023-11-09
CN119343345A (zh) 2025-01-21
CA3251489A1 (en) 2023-11-09
CL2024003362A1 (es) 2025-03-07
EP4519259A1 (en) 2025-03-12
MX2024013537A (es) 2024-12-06
PE20250007A1 (es) 2025-01-07
US20240238423A9 (en) 2024-07-18
US20230390404A1 (en) 2023-12-07
KR20250008772A (ko) 2025-01-15
AU2023264018A1 (en) 2024-11-07
TW202400589A (zh) 2024-01-01

Similar Documents

Publication Publication Date Title
CA228055S (en) Busbar
GB202201723D0 (en) New use
AU2024378219A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
IL317217A (en) BCL6 heterobifunctional 8,1-naphthyridin-2-one joints
AU2024378690A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-x l degraders
IL320722A (en) Microbiocidal tetrahydroisoquinoline derivatives
CA3310981A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
HK40124162A (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
GB202202389D0 (en) Feature Q
CA215170S (en) Welder enclosure
CA210361S (en) Spatula
GB202301355D0 (en) Use
EP4539308A4 (en) UNIT
AU2024375356A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-x l degraders
CA3310178A1 (en) Tetrahydroisoquinoline heterobifunctional bcl-xl degraders
GB202208099D0 (en) The kadugli latrine
CA239964S (en) Sprayhead
GB202305334D0 (en) Dc disconnector
CA228679S (en) Bathtub
GB202314863D0 (en) The eureka
CA216718S (en) Synthesizer
GB202304987D0 (en) Combination pharmaceutical
GB2630105B (en) Weed-control unit
GB202216306D0 (en) Combination pharmaceutical
GB202317100D0 (en) Combination